Future Medication Costs and Lifetime Projections: A Clinical Pearl for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Future medication costs are a major component of special damages in personal injury cases involving chronic conditions. Learn how to project lifetime prescription expenses using pharmacy fill data, publicly available pricing, and clinical duration evidence to support life care plans and demand packages.

Future medication costs represent one of the largest -- and most frequently undervalued -- components of special damages in personal injury cases involving chronic or permanent conditions. When a plaintiff will need ongoing prescription medications for years or decades after settlement, the projected lifetime cost of those prescriptions is a recoverable damages element that can add substantial value to the case.

• Future medication costs are recoverable special damages when pharmacy records and clinical evidence establish that the plaintiff will require ongoing prescriptions
• Lifetime projections rely on three data points: current medication regimen, expected duration of need, and publicly available retail or cash pricing
• LienScripts tracks every medication dispensed and generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents treatment trajectory and clinical prognosis for each drug
• Pharmacy fill patterns showing stable, long-term use provide the evidentiary foundation for projecting future need
• Attorneys who include pharmacy-supported future cost projections in demand packages recover significantly more in special damages

Why Future Medication Costs Are Undervalued

Most demand packages address past medical expenses with precision -- every bill, every receipt, every pharmacy fill. But future medication costs often receive only a vague estimate or are omitted entirely. This is a missed opportunity. A 35-year-old plaintiff who will need gabapentin, a muscle relaxant, and an NSAID for the rest of their life faces decades of prescription expenses that, at publicly available retail or cash prices, can total hundreds of thousands of dollars over a lifetime.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When I review a case where a plaintiff has been on a stable three-drug regimen for twelve months with no indication of discontinuation, the clinical evidence supports projecting that regimen into the future. The pharmacy fill history shows consistent refills, the prescriber continues to authorize the medications at follow-ups, and the underlying condition -- neuropathic pain, chronic inflammation, muscle spasticity -- is not expected to resolve. That is the foundation for a defensible lifetime cost projection."

Building the Projection: Three Components

Component 1: Current Medication Regimen

The starting point is the plaintiff's current medication list, confirmed by recent pharmacy fill data. LienScripts pharmacy records document every active medication, dose, frequency, and days supply. This is not a self-reported medication list -- it is a verified dispensing record that establishes exactly what the plaintiff is currently taking.

For each medication, document:

• Drug name, strength, and dosage form
• Daily dose and frequency
• Monthly quantity dispensed
• Date therapy was initiated
• Duration of continuous use to date

Component 2: Expected Duration of Need

Clinical evidence determines how long the plaintiff will need each medication. Several factors support long-term or lifetime projections:

Stable refill patterns. A plaintiff who has filled gabapentin monthly for 14 consecutive months with no dose reductions or discontinuation attempts demonstrates a stable, ongoing need. The refill pattern evidence from pharmacy records is the most objective indicator of continued need.

Chronic diagnosis. Conditions such as post-traumatic neuropathy, chronic regional pain syndrome, degenerative disc disease, and traumatic arthritis are recognized as permanent or long-duration conditions. When the plaintiff's diagnosis falls into a chronic category, lifetime medication need is clinically supported.

Dose stability. A medication regimen that has stabilized at a consistent dose -- not escalating, not tapering -- suggests the plaintiff has reached a maintenance level that they will continue indefinitely. This is stronger evidence of future need than a regimen that is still being adjusted.

Failed discontinuation attempts. If the pharmacy record shows a gap followed by resumed filling, this may indicate an attempt to discontinue that failed because symptoms returned. As documented in the medication discontinuation and rechallenge evidence pattern, this is powerful proof that the medication is genuinely needed.

Component 3: Publicly Available Pricing

For future cost projections, use publicly available retail or cash price data that anyone can verify. Resources for current pricing include:

• GoodRx or similar discount pricing aggregators -- widely used and publicly accessible
• Pharmacy cash prices -- the price a patient would pay without insurance
• Medicare Part D published pricing -- publicly available through CMS databases
• Average wholesale price (AWP) published in standard references

Use the most conservative, defensible price point available. For branded medications with no generic equivalent, note that branded pricing applies for the foreseeable future. For generic medications, use current generic cash pricing as the baseline.

Important: Annual pharmaceutical price inflation is a documented, publicly reported phenomenon. Major drug pricing indices track year-over-year increases that historically average 3-7% for branded medications. Including a modest inflation factor in lifetime projections is appropriate and defensible.

Sample Projection Framework

Consider a 40-year-old plaintiff with a 38-year life expectancy on the following stable post-accident regimen:

When calculating future costs, multiply the verified monthly cash price by 12 months, then by the number of years of expected need. Even for inexpensive generic medications, a three-drug regimen over 38 years produces a substantial total that defense counsel cannot dismiss as speculative when supported by 12-plus months of stable pharmacy fill data.

For plaintiffs on specialty or branded medications -- biologics, branded neuropathic agents, or specialty pain formulations -- the lifetime projection can reach six or seven figures. These numbers are not inflated; they reflect the publicly documented reality of medication pricing.

Presenting Future Cost Evidence

In the Demand Package

Include a dedicated future medication costs section that presents:

1. Current medication list with pharmacy-verified dosing
2. Duration of therapy to date, established by fill history
3. Clinical basis for projecting continued need
4. Per-medication annual cost at publicly available pricing
5. Total projected lifetime cost with a stated inflation assumption

Supporting the Projection

The MERIT report from LienScripts provides the clinical narrative connecting each medication to the injury, documenting the treatment trajectory, and supporting the clinical prognosis for continued need. This pharmacist-authored document transforms raw pharmacy data into expert-level clinical opinion.

Life care planners and economist experts can incorporate LienScripts pharmacy data into their formal projections. The pharmacy fill history provides the objective medication data that these experts need to build defensible cost models.

Countering Defense Challenges

"The plaintiff might stop needing these medications."

Respond with 12-plus months of stable fill history showing no tapering, no discontinuation, and no reduction in the regimen. The clinical evidence supports projection of the current regimen, not speculation about future improvement.

"Generic prices will decrease."

While possible, this is speculative in the defendant's favor. Current pricing is the best available evidence. If anything, pharmaceutical pricing trends support the opposite assumption.

"The plaintiff could switch to cheaper alternatives."

The plaintiff's current regimen is the result of a prescriber's clinical judgment based on efficacy and tolerability. Suggesting the plaintiff should accept an inferior or untested alternative to save the defendant money is not a defensible position.

The Clinical Pearl

Future medication costs turn pharmacy records into a forward-looking damages element. LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that includes the treatment trajectory and clinical prognosis needed to support lifetime cost projections. Attorneys who build these projections using verified pharmacy data consistently recover more in special damages than those who rely on vague estimates.

Related Resources

• Refill Patterns as Objective Pain Evidence -- Using fill timing to establish ongoing need
• What Is a MERIT Report? -- Understanding the pharmacist-authored clinical summary
• Demand Package Pharmacy Records -- Integrating pharmacy documentation into demand letters